SCHEMBL15021995

SCHEMBL15021995

COc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(Oc3ncnc4[nH]c(=O)cnc34)c3ccccc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAPK12 P53778 19/20 1.00
MAPK14 Q16539 19/20 1.00
HCK P08631 17/20 1.00
SRC P12931 18/20 0.83
BRAF P15056 3/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15022017 0.91 MAPK12 (1.00) MAPK12MAPK14HCKSRCBRAF
SCHEMBL20386669 0.91 MAPK14 (0.83) MAPK12MAPK14HCKSRCBRAF
SCHEMBL20382935 0.88 MAPK14 (0.88) MAPK12MAPK14HCKSRCBRAF
SCHEMBL15034588 0.86 MAPK12 (1.00) MAPK12MAPK14HCKSRCBRAF
SCHEMBL3187135 0.84 SRC (1.00) MAPK12MAPK14HCKSRCBRAF
SCHEMBL3173219 0.84 SRC (1.00) MAPK12MAPK14HCKSRCBRAF
SCHEMBL15021859 0.83 HCK (1.00) MAPK12MAPK14HCKSRCBRAF
SCHEMBL13296481 0.83 MAPK14 (0.71) MAPK12MAPK14HCKSRC
SCHEMBL15022847 0.83 HCK (1.00) MAPK12MAPK14HCKSRCBRAF
SCHEMBL18192774 0.83 MAPK12 (0.85) MAPK12MAPK14HCKSRCBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10358445-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2019-07-23 US claimed
US-20180201611-A1 Respiratory formulations and compounds for use therein RESPIVERT LTD. (GB) 2018-07-19 US claimed
EP-2582700-B1 RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS RESPIVERT LTD (GB) 2016-11-02 EP claimed
US-8933228-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2015-01-13 US claimed
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2013-06-20 US claimed
US-10358445-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2019-07-23 US disclosed
US-20180201611-A1 Respiratory formulations and compounds for use therein RESPIVERT LTD. (GB) 2018-07-19 US disclosed
US-20180201611-A1 Respiratory formulations and compounds for use therein RESPIVERT LTD. (GB) 2018-07-19 US disclosed
EP-2582700-B1 RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS RESPIVERT LTD (GB) 2016-11-02 EP disclosed
US-8933228-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2015-01-13 US disclosed
US-8933228-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2015-01-13 US disclosed
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2013-06-20 US disclosed
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN TSLP, CCL11, RORB MAPK12 2494/4885MAPK14 2307/4885HCK 4116/4885
US-10358445-B2 Respiratory formulations and compounds for use therein TSLP, CCL11, RORB MAPK12 2494/4885MAPK14 2307/4885HCK 4116/4885
US-20180201611-A1 Respiratory formulations and compounds for use therein TSLP, CCL11, RORB MAPK12 2494/4885MAPK14 2307/4885HCK 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.